3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
6
Other hematologic neoplasm
4
Plasma cell
2
Other neoplasm
2
Myeloid
2
Sarcoma
1
Conditions
Multiple Myeloma
420
Lymphoma
53
Recurrence
42
Neoplasms, Plasma Cell
33
Hematologic Neoplasms
33
Immunoglobulin Light-chain Amyloidosis
29
Smoldering Multiple Myeloma
26
Lymphoma, Non-Hodgkin
25
Leukemia, Myeloid, Acute
20
Leukemia, Lymphocytic, Chronic, B-Cell
20
Neoplasms
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Hodgkin Disease
17
Myelodysplastic Syndromes
16
Monoclonal Gammopathy of Undetermined Significance
13
Waldenstrom Macroglobulinemia
11
Lymphoma, Mantle-Cell
11
Leukemia
11
Prostatic Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
10
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Breast Neoplasms
10
Paraproteinemias
9
Ovarian Neoplasms
9
Lung Neoplasms
8
Leukemia, Plasma Cell
8
Amyloidosis
8
Melanoma
7
Lymphoma, Follicular
7
Lymphoma, B-Cell, Marginal Zone
7
Interventions
CLR1404
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Immunoproliferative Disorders
×
Plasma cell
×
90 days
×
Clear all
NCT07075185
2026-04-24
inMMyCAR
Kelonia Therapeutics, Inc.
Phase 1
Recruiting
70 enrolled
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled